Certified by Founder
Lodge
T-Therapeutics Ltd
start up
United Kingdom
- Cambridge
- 16/11/2023
- Series A
- $59,707,000
T-Therapeutics is a next-generation TCR company, spun out from the University of Cambridge, deeply rooted in world-leading academic science. We are developing ‘optimal’ TCR based therapeutics using our proprietary OpTiMus® platform, based on a fully humanized TCR mouse that provides an almost unlimited source of unique, antigen-specific human TCRs.
We combine world-leading expertise in mouse genome engineering, deep expertise in biopharmaceutical drug development, single cell genomics, machine-learning and structural biology, anchored in a culture of creativity and collaboration.
- Industry Biotechnology Research
- Website https://t-therapeutics.com/
- LinkedIn https://www.linkedin.com/company/t-therapeutics/about/
Feltsense | $5,100,000 | (Feb 5, 2026)
Stratus Medical | $10,000,000 | (Feb 5, 2026)
beHuman Corp. | $4,000,000 | (Feb 5, 2026)
Boomband | $4,000,000 | (Feb 5, 2026)
Bedrock Robotics | $270,000,000 | (Feb 5, 2026)
Fibr AI | $7,500,000 | (Feb 5, 2026)
Expert Intelligence™ | $4,700,000 | (Feb 5, 2026)
Positron AI | $230,000,000 | (Feb 5, 2026)
Chamber(US) | $60,000,000 | (Feb 5, 2026)
SENAI | $6,200,000 | (Feb 5, 2026)
OneDome | $25,000,000 | (Feb 4, 2026)
Naoma AI | $440,000 | (Feb 4, 2026)